CanBas Co., Ltd. researches and develops anticancer drugs. The company develops CBP501, which acts as a calmodulin, a protein involved in various cell functions for treatment of cancer; and CBS9106, a reversible XPO1 inhibitor for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.